TBIO.jpg
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
03 août 2021 01h00 HE | Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
TBIO.jpg
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
22 juin 2021 01h00 HE | Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
TBIO.jpg
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
07 juin 2021 07h30 HE | Translate Bio, Inc.
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to...
TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
24 mai 2021 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference
18 mai 2021 10h00 HE | Translate Bio, Inc.
– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into...
TBIO.jpg
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
06 mai 2021 16h13 HE | Translate Bio, Inc.
-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year...
TBIO.jpg
Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit
28 avr. 2021 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Key Leadership Additions and Promotions
19 avr. 2021 07h30 HE | Translate Bio, Inc.
-- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary...
TBIO.jpg
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
19 avr. 2021 07h30 HE | Translate Bio, Inc.
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy...
TBIO.jpg
Translate Bio Appoints Dr. Rand Sutherland as President
22 mars 2021 07h30 HE | Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...